DEA to Temporarily Place 7-Hydroxymitragynine in Schedule I of Controlled Substances Act

The Drug Enforcement Administration (DEA) intends to issue a temporary order to place 7-hydroxymitragynine, a component of the plant Mitragyna speciosa (kratom), in Schedule I of the Controlled Substances Act. This action is prompted by a rapid escalation in reported incidents, including drug dependence, withdrawal syndrome, and deaths, as indicated by data from poison centers and the FDA-Adverse Event Reporting System (FAERS).

Context

7-hydroxymitragynine is derived from kratom, a plant used for its stimulant and sedative effects. The DEA's action is based on increasing reports of adverse effects, including dependency and fatalities, connected to its use. Previous studies have raised questions about the safety profile of kratom and its components, leading to calls for regulation.

Why it matters

The DEA's decision to classify 7-hydroxymitragynine as a Schedule I substance highlights growing concerns about the safety and potential risks associated with kratom. This classification restricts its legal availability and may impact users who rely on it for pain management or other purposes. The move reflects a broader trend of regulatory scrutiny on substances linked to health risks and public safety.

Implications

This decision may limit access to kratom for individuals who use it for pain relief or other therapeutic purposes. It could also lead to increased legal consequences for possession and distribution of 7-hydroxymitragynine. The classification may influence future research and discussions around the safety and efficacy of kratom and similar substances.

What to watch

The temporary scheduling will likely lead to further discussions about the regulation of kratom and its derivatives. Stakeholders, including advocates for kratom users and public health officials, may mobilize to respond to the DEA's action. Monitoring of related health incidents and public reactions will be crucial in the coming months.